JP2008504266A - 異脂肪血症を治療するための化合物及び方法 - Google Patents
異脂肪血症を治療するための化合物及び方法 Download PDFInfo
- Publication number
- JP2008504266A JP2008504266A JP2007518182A JP2007518182A JP2008504266A JP 2008504266 A JP2008504266 A JP 2008504266A JP 2007518182 A JP2007518182 A JP 2007518182A JP 2007518182 A JP2007518182 A JP 2007518182A JP 2008504266 A JP2008504266 A JP 2008504266A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- trifluoromethyl
- amino
- dihydro
- quinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 **1C=C(*)C(F)=C*C=C1 Chemical compound **1C=C(*)C(F)=C*C=C1 0.000 description 2
- BDNFCSNNCDPVOM-NCJJPXCVSA-N CC(C)OC(N(C(C)C[C@@H]1NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2c1cc(C(F)(F)[F]N/N=N\NC(C1)CN1C(c1ccccc1)c1ccccc1)cc2)=O Chemical compound CC(C)OC(N(C(C)C[C@@H]1NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2c1cc(C(F)(F)[F]N/N=N\NC(C1)CN1C(c1ccccc1)c1ccccc1)cc2)=O BDNFCSNNCDPVOM-NCJJPXCVSA-N 0.000 description 1
- FVPPLRDSFQDFLX-UHFFFAOYSA-N CCC(CC#N)N Chemical compound CCC(CC#N)N FVPPLRDSFQDFLX-UHFFFAOYSA-N 0.000 description 1
- DGXMMPYBSIRUKJ-KNQAVFIVSA-N CC[C@H](C1)N(C(OC(C)C)=O)c2ccc(C(F)(F)F)cc2[C@H]1N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1n[n](CC(N)=O)nn1 Chemical compound CC[C@H](C1)N(C(OC(C)C)=O)c2ccc(C(F)(F)F)cc2[C@H]1N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1n[n](CC(N)=O)nn1 DGXMMPYBSIRUKJ-KNQAVFIVSA-N 0.000 description 1
- ZOYXDRDJRPCCTD-MRVPVSSYSA-N CC[C@H](CC#N)NC(OC(C)(C)C)=O Chemical compound CC[C@H](CC#N)NC(OC(C)(C)C)=O ZOYXDRDJRPCCTD-MRVPVSSYSA-N 0.000 description 1
- SRQMEMUIMPJQNO-MRXNPFEDSA-N CC[C@H](CC(NC(OCc1ccccc1)=O)=O)Nc1ccc(C(F)(F)F)cc1 Chemical compound CC[C@H](CC(NC(OCc1ccccc1)=O)=O)Nc1ccc(C(F)(F)F)cc1 SRQMEMUIMPJQNO-MRXNPFEDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58270804P | 2004-06-24 | 2004-06-24 | |
| US62724104P | 2004-11-12 | 2004-11-12 | |
| US66486205P | 2005-03-24 | 2005-03-24 | |
| PCT/US2005/021789 WO2006012093A1 (en) | 2004-06-24 | 2005-06-22 | Compounds and methods for treating dyslipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504266A true JP2008504266A (ja) | 2008-02-14 |
| JP2008504266A5 JP2008504266A5 (enExample) | 2008-08-07 |
Family
ID=35056992
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518182A Pending JP2008504266A (ja) | 2004-06-24 | 2005-06-22 | 異脂肪血症を治療するための化合物及び方法 |
| JP2007518296A Expired - Fee Related JP4836945B2 (ja) | 2004-06-24 | 2005-06-23 | 異常脂質血症を治療するための化合物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518296A Expired - Fee Related JP4836945B2 (ja) | 2004-06-24 | 2005-06-23 | 異常脂質血症を治療するための化合物および方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20080269284A1 (enExample) |
| EP (3) | EP1761521A1 (enExample) |
| JP (2) | JP2008504266A (enExample) |
| KR (1) | KR20070041452A (enExample) |
| CN (1) | CN1972932B (enExample) |
| AT (1) | ATE528304T1 (enExample) |
| AU (2) | AU2005267436A1 (enExample) |
| BR (2) | BRPI0512523A (enExample) |
| CA (2) | CA2570688A1 (enExample) |
| CR (1) | CR8831A (enExample) |
| CY (1) | CY1112124T1 (enExample) |
| DK (1) | DK1761522T3 (enExample) |
| EA (2) | EA200700119A1 (enExample) |
| EC (2) | ECSP067095A (enExample) |
| ES (1) | ES2372291T3 (enExample) |
| HR (1) | HRP20110761T1 (enExample) |
| IL (2) | IL180277A (enExample) |
| MA (2) | MA28730B1 (enExample) |
| MX (2) | MXPA06014716A (enExample) |
| NO (2) | NO20070468L (enExample) |
| NZ (1) | NZ550978A (enExample) |
| PL (1) | PL1761522T3 (enExample) |
| PT (1) | PT1761522E (enExample) |
| RS (1) | RS52064B (enExample) |
| SI (1) | SI1761522T1 (enExample) |
| WO (2) | WO2006012093A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7749992B2 (en) * | 2003-10-08 | 2010-07-06 | Eli Lilly And Company | Compounds and methods for treating dislipidemia |
| BRPI0508966A (pt) | 2004-03-26 | 2007-08-21 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| EA200700119A1 (ru) | 2004-06-24 | 2007-10-26 | Эли Лилли Энд Компани | Соединения и способы лечения дислипидемии |
| WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2157190B1 (en) * | 2007-05-17 | 2017-05-03 | EA Pharma Co., Ltd. | Method of measuring the activity of lipid-modified enzyme |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| AR077208A1 (es) * | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
| JP2013503135A (ja) | 2009-08-26 | 2013-01-31 | サノフイ | 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| HRP20180032T8 (hr) * | 2012-06-11 | 2018-12-14 | Tacurion | Postupak dobivanja spoja 4,4,7-trifluor-1,2,3,4-tetrahidro-5h-1-benzazepina i međuprodukta u njegovoj sintezi |
| CN103958501B (zh) * | 2012-07-16 | 2016-08-17 | 上海恒瑞医药有限公司 | 苯并七元杂环类衍生物、其制备方法及其在医药上的应用 |
| HUE042932T2 (hu) * | 2014-02-05 | 2019-07-29 | Dezima Pharma B V | Koleszterinészter-transzferprotein (CETP) inhibitor és az említett inhibitort tartalmazó gyógyászati készítmény szív- és érrendszeri betegségek kezelésében vagy megelõzésében való alkalmazásra |
| CN103833637B (zh) * | 2014-03-31 | 2016-01-06 | 武汉武药制药有限公司 | 一种制备依塞曲匹（Evacetrapib）中间体的方法 |
| US10106501B2 (en) | 2015-06-09 | 2018-10-23 | Abbvie Inc. | Nuclear receptor modulators |
| WO2016198908A1 (en) | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Ror nuclear receptor modulators |
| WO2024249901A2 (en) * | 2023-06-01 | 2024-12-05 | Nico Therapeutics, Inc. | Compounds, compositions, and methods |
| CN117263810A (zh) * | 2023-09-19 | 2023-12-22 | 上海凌凯医药科技有限公司 | 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000095764A (ja) * | 1998-09-17 | 2000-04-04 | Pfizer Prod Inc | 環化４―カルボキシアミノ―２―メチル―１，２，３，４―テトラヒドロキノリン |
| JP2002526476A (ja) * | 1998-09-17 | 2002-08-20 | ファイザー・プロダクツ・インク | Ｃｅｔｐ阻害剤としての４−アミノ置換−２−置換−１，２，３，４−テトラヒドロキノリン |
| WO2005095409A2 (en) * | 2004-04-02 | 2005-10-13 | Tanabe Seiyaku Co., Ltd. | Tetrahydroquinoline derivatives and a process for preparing the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2402506A1 (fr) * | 1977-09-09 | 1979-04-06 | Guelennec Emile Le | Cisaille pour la decoupe de ferrailles de grandes dimensions |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
| CO5271716A1 (es) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| PL366584A1 (en) * | 2001-04-30 | 2005-02-07 | Pfizer Products Inc. | Compounds useful as intermediates |
| SI1533292T1 (sl) | 2002-08-30 | 2007-08-31 | Japan Tobacco Inc | Dibenzilaminska spojina in njena medicinska uporaba |
| PL376156A1 (en) | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| JP2006523218A (ja) | 2003-03-04 | 2006-10-12 | 高砂香料工業株式会社 | 光学活性アミン類の製造方法 |
| US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| US7749992B2 (en) | 2003-10-08 | 2010-07-06 | Eli Lilly And Company | Compounds and methods for treating dislipidemia |
| BRPI0508966A (pt) | 2004-03-26 | 2007-08-21 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| EA200700119A1 (ru) | 2004-06-24 | 2007-10-26 | Эли Лилли Энд Компани | Соединения и способы лечения дислипидемии |
| WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| AR077208A1 (es) * | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
-
2005
- 2005-06-22 EA EA200700119A patent/EA200700119A1/ru unknown
- 2005-06-22 MX MXPA06014716A patent/MXPA06014716A/es not_active Application Discontinuation
- 2005-06-22 JP JP2007518182A patent/JP2008504266A/ja active Pending
- 2005-06-22 BR BRPI0512523-5A patent/BRPI0512523A/pt not_active Application Discontinuation
- 2005-06-22 EP EP05768995A patent/EP1761521A1/en not_active Withdrawn
- 2005-06-22 KR KR1020067027038A patent/KR20070041452A/ko not_active Ceased
- 2005-06-22 AU AU2005267436A patent/AU2005267436A1/en not_active Abandoned
- 2005-06-22 US US11/570,540 patent/US20080269284A1/en not_active Abandoned
- 2005-06-22 WO PCT/US2005/021789 patent/WO2006012093A1/en not_active Ceased
- 2005-06-22 CA CA002570688A patent/CA2570688A1/en not_active Abandoned
- 2005-06-23 RS RS20110559A patent/RS52064B/sr unknown
- 2005-06-23 CA CA2570673A patent/CA2570673C/en not_active Expired - Fee Related
- 2005-06-23 EA EA200700120A patent/EA012585B1/ru not_active IP Right Cessation
- 2005-06-23 HR HR20110761T patent/HRP20110761T1/hr unknown
- 2005-06-23 AT AT05763328T patent/ATE528304T1/de active
- 2005-06-23 BR BRPI0512516-2A patent/BRPI0512516A/pt active Search and Examination
- 2005-06-23 MX MXPA06014706A patent/MXPA06014706A/es active IP Right Grant
- 2005-06-23 EP EP11184746A patent/EP2479175A1/en not_active Withdrawn
- 2005-06-23 CN CN2005800206855A patent/CN1972932B/zh not_active Expired - Fee Related
- 2005-06-23 NZ NZ550978A patent/NZ550978A/en not_active IP Right Cessation
- 2005-06-23 ES ES05763328T patent/ES2372291T3/es not_active Expired - Lifetime
- 2005-06-23 PT PT05763328T patent/PT1761522E/pt unknown
- 2005-06-23 EP EP05763328A patent/EP1761522B1/en not_active Expired - Lifetime
- 2005-06-23 JP JP2007518296A patent/JP4836945B2/ja not_active Expired - Fee Related
- 2005-06-23 PL PL05763328T patent/PL1761522T3/pl unknown
- 2005-06-23 WO PCT/US2005/022389 patent/WO2006002342A1/en not_active Ceased
- 2005-06-23 DK DK05763328.1T patent/DK1761522T3/da active
- 2005-06-23 AU AU2005258241A patent/AU2005258241B2/en not_active Ceased
- 2005-06-23 SI SI200531438T patent/SI1761522T1/sl unknown
- 2005-06-23 US US11/570,542 patent/US7786108B2/en not_active Expired - Fee Related
-
2006
- 2006-12-19 EC EC2006007095A patent/ECSP067095A/es unknown
- 2006-12-19 EC EC2006007098A patent/ECSP067098A/es unknown
- 2006-12-22 CR CR8831A patent/CR8831A/es unknown
- 2006-12-24 IL IL180277A patent/IL180277A/en not_active IP Right Cessation
- 2006-12-24 IL IL180276A patent/IL180276A0/en unknown
- 2006-12-29 MA MA29596A patent/MA28730B1/fr unknown
- 2006-12-29 MA MA29595A patent/MA28729B1/fr unknown
-
2007
- 2007-01-24 NO NO20070468A patent/NO20070468L/no not_active Application Discontinuation
- 2007-01-24 NO NO20070470A patent/NO20070470L/no not_active Application Discontinuation
-
2010
- 2010-04-20 US US12/763,344 patent/US20100204207A1/en not_active Abandoned
-
2011
- 2011-11-25 CY CY20111101160T patent/CY1112124T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000095764A (ja) * | 1998-09-17 | 2000-04-04 | Pfizer Prod Inc | 環化４―カルボキシアミノ―２―メチル―１，２，３，４―テトラヒドロキノリン |
| JP2002526476A (ja) * | 1998-09-17 | 2002-08-20 | ファイザー・プロダクツ・インク | Ｃｅｔｐ阻害剤としての４−アミノ置換−２−置換−１，２，３，４−テトラヒドロキノリン |
| WO2005095409A2 (en) * | 2004-04-02 | 2005-10-13 | Tanabe Seiyaku Co., Ltd. | Tetrahydroquinoline derivatives and a process for preparing the same |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008504266A (ja) | 異脂肪血症を治療するための化合物及び方法 | |
| JP2007530550A (ja) | 異脂肪血症を治療するための化合物および方法 | |
| CN105682656B (zh) | 调节法尼醇x受体的组合物和方法 | |
| CA2828456C (en) | N-benzl-amino-carboxamide inhibitors of the sodium channel | |
| RU2158731C2 (ru) | Производные ароилпиперидина или их соли, фармацевтический препарат на их основе и способ их получения | |
| JP3218037B2 (ja) | 喘息および呼吸器官の炎症の治療に有用なヘテロサイクリックアミン類 | |
| JP5209670B2 (ja) | カリウムチャンネル機能のヘテロ環インヒビター | |
| CN100402523C (zh) | 杂环化合物及以其为有效成分的抗肿瘤药 | |
| JP2001519812A (ja) | ソマトスタチン作動薬 | |
| WO2011007819A1 (ja) | ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬 | |
| JPH11501640A (ja) | ５−ｈｔ▲下４▼拮抗作用を有するジ−置換１，４−ピペリジンエステル類及びアミド類 | |
| TW201623295A (zh) | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 | |
| JPH08169884A (ja) | シクロプロパクロメンカルボン酸誘導体 | |
| EP1019373A1 (fr) | Nouveaux composes antagonistes selectifs du recepteur nk 3? humain, procede pour leur obtention et compositions pharmaceutiques les contenant | |
| JP2005518375A (ja) | Ｇタンパク質結合受容体（ｇｐｃｒ）のためのリガンドとしてのテトラヒドロカルバゾール誘導体 | |
| TW201522291A (zh) | 胍基苯甲酸酯化合物 | |
| CA2841897A1 (en) | Novel compound having parp inhibitory activity | |
| KR100416674B1 (ko) | 크로몬유도체 | |
| JPH07500604A (ja) | 高血圧治療用エチルアラニンアミノジオール化合物 | |
| CN107840826B (zh) | 1h-吲唑类衍生物及其作为ido抑制剂的用途 | |
| FR2824828A1 (fr) | Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant | |
| CN101434570B (zh) | 吡咯烷衍生物及其制备方法和应用 | |
| JP2018519252A (ja) | ファルネソイドｘ受容体をモジュレートするのに有用である縮合三環式ピラゾール誘導体 | |
| JP7449300B2 (ja) | ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物 | |
| CN1972927A (zh) | 用于治疗血脂障碍的化合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080619 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080619 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110511 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110524 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111122 |